The methylation status of genes in hydatidiform mole and choriocarcinoma and its significance is relatively unexplored. We investigated the methylation status of the promoter regions of six genes, p16, HIC-1, TIMP3, GSTP1, death-associated protein kinase (DAPK), and E-cadherin in 54 hydatidiform moles, five choriocarcinomas, and 10 first trimester placenta by methylation-specific polymerase chain reaction (PCR). Immunohistochemical expression of p16, TIMP3, and E-cadherin, and quantitative real-time RT-PCR of p16 was also performed. Among the six genes examined, the promoter region of four genes (E-cadherin, HIC-1, p16, TIMP3) in choriocarcinoma and three genes (E-cadherin, HIC-1, p16) in hydatidiform mole exhibited aberrant methylation whereas none was hypermethylated in normal placenta. There was a significant correlation between methylation and reduced expression of p16, E-cadherin, and TIMP3 (P < 0.001). Fifteen of the 54 patients with hydatidiform mole developed gestational trophoblastic neoplasia requiring chemotherapy. Promoter hypermethylation of p16 alone, or combined with E-cadherin, was significantly correlated to such development (P ‫؍‬ 0.001, 0.0005, respectively). Hypermethylation of multiple genes, especially p16, might be related to the subsequent development of gestational trophoblastic neoplasia. Hydatidiform mole and choriocarcinoma are two major subtypes of gestational trophoblastic disease (GTD) in Orientals. The reported incidence of GTD is approximately 1 in 500 to 1 in 1000 pregnancies in Asia, two to ten times higher than that in United States and Europe.
Hydatidiform mole and choriocarcinoma are two major subtypes of gestational trophoblastic disease (GTD) in Orientals. The reported incidence of GTD is approximately 1 in 500 to 1 in 1000 pregnancies in Asia, two to ten times higher than that in United States and Europe. 1, 2 Choriocarcinoma is a highly malignant epithelial tumor arising from the trophoblast of any type of gestational event, most often a hydatidiform mole. Hydatidiform mole represents abnormally formed placenta characterized by swelling of chorionic villi and excessive proliferation of trophoblast. Although not a frank malignancy, hydatidiform mole may behave in an aggressive way with a predisposition for malignant transformation. About 8 to 30% of patients with hydatidiform mole will develop gestational trophoblastic neoplasia and require chemotherapy. 1, 2 Most choriocarcinomas are related to previous hydatidiform moles. Similar to other human cancers, neoplastic transformation of trophoblast is likely to be a multistep process and involves multiple genetic alterations including activation of oncogenes and inactivation of tumor suppressor genes. 3, 4 Potential biological markers related to malignant transformation of trophoblast include c-erbB-2, 5 cyclin E, 6 DOC-2/hDab2, 7 Ras GTPase activating protein, 8 telomerase activity, 9 apoptotic index, 10, 11 and matrix metalloproteinases, 12 but no molecular parameter can currently replace serial serum human chorionic gonadotrophin (hCG) titers as the mainstay for predicting gestational trophoblastic neoplasia.
Promoter hypermethylation has recently been found to be an important epigenetic mechanism causing gene inactivation. Tumor suppressor genes, involving cell cycle regulation (p16), DNA repair and protection (BRCA1 and GSTP1), apoptosis (DAPK), cell adherence and metastasis process (E-cadherin, TIMP3), may be silenced by promoter CpG island methylation in many human tumors, thus contribute to carcinogenesis. Previously, we have shown that hypermethylation of E-cadherin may be related to its reduced expression in hydatidiform mole using a relatively small number of cases. 13 While hypermethylation of the H19 and TFPI-2 genes has been reported in choriocarcinoma, 14 -16 little is currently known about the methylation status of tumor suppressor genes in GTD.
In this study, we examined the frequency of methylation of six genes, p16, E-cadherin, TIMP3, DAPK, GSTP1, and HIC-1, which are known to undergo epigenetic inactivation in other human cancers, in 54 hydatidiform moles, five human gestational choriocarcinomas, and 10 normal first trimester placentas by methylation-specific polymerase chain reaction (MSP). Expressions of p16, TIMP3, and E-cadherin in these samples were investigated by immunohistochemistry and quantitative real-time RT-PCR. In addition, the relationship between the methylation status and subsequent development of gestational trophoblastic neoplasia was analyzed.
Materials and Methods

Patients and Samples
All specimens of trophoblastic tissue were collected at the Department of Pathology, University of Hong Kong, Queen Mary Hospital. Clinically and ultrasonographically suspected cases of hydatidiform moles were suction evacuated. First trimester samples were obtained after induced abortion by suction evacuation. Fresh chorionic villi, molar vesicles, and decidua were dissected, selected and snap-frozen in liquid nitrogen, and stored at Ϫ70°C. The rest of tissue was fixed in formalin. Frozen tissue blocks of 10 normal first trimester placentas (gestational age 9.0 Ϯ 2.2 weeks) and 54 hydatidiform moles with follow-up data were selected for this study. The patients' age ranged from 16 to 51 (mean, 32.7) while the gestational age of the hydatidiform mole ranged from 6 weeks to 34 weeks (mean, 13.6 weeks). Archival formalin-fixed, paraffin-embedded tissue blocks from five choriocarcinomas before chemotherapy were also retrieved. The histological features of these cases were assessed using generally agreed and accepted diagnostic criteria.
1,2 Some of the hydatidiform moles had also been examined previously, by chromosome in situ hybridization and genotyping using DNA extracted from lasercapture-microdissected tissues. 17 Thirty-nine of the 54 hydatidiform moles were complete moles while 15 were partial moles. Gestational trophoblastic neoplasia was diagnosed if there was a plateau in hCG level for 4 weeks or if there was a further increase in hCG for 3 consecutive weeks when pregnancy was excluded. 18 According to these criteria, 39 patients had spontaneous regression of the hydatidiform mole while the other 15 cases developed gestational trophoblastic neoplasia and received chemotherapy.
MSP
Genomic DNA extracted from the frozen tissues was modified by sodium bisulfite as previously described with minor modification. 19, 20 Briefly, one g genomic DNA was denatured by adding freshly prepared sodium hydroxide (final concentration of 0.3 mol/L) at 37°C for 10 minutes, and 95°C for 2 minutes. After cooling down to room temperature, hydroquinone (30 mmol/L) and sodium bisulfite (3.6 mol/L, pH 5.0) were added. The mixture was then incubated at 55°C for 15 to 16 hours in the dark. Wizard DNA Cleanup System (Promega, Madison, WI) was applied to purify the sodium bisulfite-modified DNA according to manufacturer's recommendations. The modified DNA was then incubated in 0.3 mol/L sodium hydroxide at 37°C for 15 minutes, then neutralized by adding sodium acetate (pH 4.0). The DNA was ethanolprecipitated and re-suspended in 30 l of 10 mmol/L Tris water (pH 8.0). The primers and reaction conditions of MSP for the investigated genes were listed in Table 1 . Five l of each PCR products were separated on 2.5% agarose gel, which was stained with ethidium bromide, and directly visualized under UV illumination. DNA from normal placenta treated with SssI methylase (New England Biolabs, Beverly, MA) was used as a methylation-positive control. Genomic DNAs without bisulfite modification were used as negative control in both methylated and unmethylated reactions. Samples demonstrated to have methylation in either gene were repeated for confirmation.
Immunohistochemistry
Sections 5-m thick were cut from representative paraffin blocks of each case and mounted on 2% aminopropyltriethoxysilane-coated glass slides. To avoid antigen loss after preparation, immunostaining was carried out within 48 hours. After microwave pretreatment for antigen retrieval, primary antibodies for E-cadherin (monoclonal, at a dilution 1:150; Transduction Laboratories, Lexington, KY), p16 (monoclonal, at a dilution 1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), TIMP3 (monoclo- 
Quantitative Real-Time RT-PCR
Twelve hydatidiform moles, six subsequently regressed, and six developed gestational trophoblastic neoplasia, were selected for quantitative RT-PCR analysis according to previously published procedures. 22 First-strand cDNA was synthesized from DNase-treated total RNA with oligo-dT primer and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA), followed by PCR amplification using the corresponding gene-specific primers. Primer sequences for p16 are as follows: 5Ј-TAC GGT CGG AGG CCG ATC CAG GTC-3Ј (sense) and 5Ј-GGG GAT GTC TGA GGG ACC TTC CGC -3Ј (antisense). GAPDH (housekeeping gene used as control in RT-PCR study): 5Ј-CTC AGA CAC CAT GGG GAA-3Ј (sense) and 5Ј-ATG ATC TTG AGG CTG TTG-3Ј (antisense). Quantitative real-time RT-PCR was performed in a 25-l reaction, which included 1 l of cDNA template, 50 mmol/L KCl, 3 mmol/L MgCl 2 , 10 mmol/L Tris-HCl, pH 9.0, 0.05 mmol/L of each dNTP, 0.2 mmol/L of each forward and reverse oligo primer, 2.5 U of TaqDNA polymerase (Amersham Biosciences, Piscataway, NJ), and 0.1X SYBR Green I (Molecular Probes, Eugene, OR), using an iCycler iQ Multi Color Real Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA). Each PCR reaction was optimized to ensure that a single PCR product was amplified and no product corresponding to primer-dimer pairs was present. PCR reactions of each template were performed in duplicate in one 96-well plate. The PCR cycling conditions were as follows: 95°C for 3 minutes followed by 50 cycles of three steps at 95°C for 30 seconds, 68°C for 30 seconds, and then 72°C for 30 seconds. The relative fold change method was used to determine the relative quantitative gene expression for p16 compared with the GAPDH. 
Statistical Analysis
Results
MSP
We have analyzed the methylation status of the promoter region of six genes (p16, E-cadherin, TIMP3, DAPK, GSTP1, and HIC-1) in choriocarcinoma, hydatidiform mole, and normal placenta. In normal placenta, only unmethylated alleles could be detected for all of the six investigated genes.
The results of MSP in choriocarcinoma and hydatidiform mole were shown in Table 2 . Representative examples of the MSP analysis were shown in Figure 1 . At least one gene was methylated in 64% (38 of 59) of the GTD samples including 61% (33 of 54) of hydatidiform mole and 100% (5 of 5) of choriocarcinoma. Four genes showed aberrant methylation in choriocarcinoma at the frequencies of 40% (2 of 5) for E-cadherin, p16, TIMP3, and 60% (3 of 5) for HIC-1. Three genes showed aberrant methylation in hydatidiform mole at frequencies of 13.0% (7 of 54) for E-cadherin, 20.4% (11 of 54) for p16 and 40.7% (22 of 54) for HIC-1. No significant correlation was found between methylation status of E-cadherin, p16, and HIC-1 (P Ͼ 0.05).
The findings regarding correlation between methylation status of these genes, in isolation or combination, with subsequent development of gestational trophoblastic neoplasia was tabulated in Table 3 . The adjusted P value for multiple testing was estimated by the Bonferroni procedure ␣' ϭ 1 Ϫ (1 Ϫ 0.05) 1/7 ϭ 0.007. Those hydatidiform moles, which subsequently developed gestational trophoblastic neoplasia, were found to have significantly more frequent p16 promoter hypermethylation comparing to those that subsequently regressed (P ϭ 0.001, Fisher's exact test, OR ϭ 13.714, 95% CI ϭ 2.898 to 62.899). The sensitivity and specificity of p16 hypermethylation in predicting subsequent development of gestational trophoblastic neoplasia were 53.5% (8 of 15) and 92.3% (36 of 39), respectively. Methylation status of E-cadherin and HIC-1 by themselves showed no such correlation (P ϭ 0.084 and 0.492, respectively). However, when the E-cadherin and p16 methylation status were analyzed together, statistically significant correlation between promoter hypermethylation of either or both genes and development of gestational trophoblastic neoplasia was demonstrated (P Ͻ 0.0005, Fisher's exact test, OR ϭ 18.7, 95% CI ϭ 4.256 to 82.161). Moreover, the sensitivity and specificity in predicting subsequent development of gestational trophoblastic neoplasia became 73.5% (11 of 15) and 87.2% (34 of 39), respectively. On the other hand, combined analysis on the E-cadherin, p16, and HIC-1 methylation status showed no significant correlation to the development of gestational trophoblastic neoplasia (P ϭ 0.037, more than adjusted P-value 0.013, Fisher's exact test) with sensitivity and specificity of 80% (12 of 15) and 51.3% (20 of 39), respectively.
Regression analysis showed that E-cadherin, HIC-1, and p16 promoter methylation neither correlated with patients' age (P ϭ 0.12, 0.24, and 0.46, the adjusted R 2 ϭ 0.028, 0.0080, and 0, respectively) nor with the gestational age of hydatidiform moles (P ϭ 0.92, 0.97, and 0.39, respectively, the adjusted R 2 ϭ 0) in our studied samples.
Methylated alleles of DAPK and GSTP1 cannot be detected in either choriocarcinoma or hydatidiform mole. Aberrant methylation of TIMP3 was detectable in choriocarcinoma but not in hydatidiform mole. 
Immunohistochemical Analysis
To determine whether the observed aberrant methylation was associated with gene silencing, we examined the expression of p16, E-cadherin, and TIMP3 in 54 hydatidiform moles and five choriocarcinomas using immunohistochemistry. P16 immunoreactivity was mainly demonstrated in the nuclei of the trophoblasts while TIMP3 and E-cadherin expression was predominantly found at the cytoplasm and cell membrane. Reduced expression was defined if less than 80% trophoblastic cells showed positive staining. 21 Table 4 and Figure 2 showed the findings for the immunohistochemical staining of these three proteins and their relationship with the MSP results. A close correlation was noted between hypermethylation of p16, E-cadherin, and TIMP3 and reduced expression of the corresponding protein (P Ͻ 0.001).
Quantitative Real-Time RT-PCR
Six cases of hydatidiform mole which had subsequently developed gestational trophoblastic neoplasia, and six cases which had subsequently regressed, were further analyzed by quantitative real-time RT-PCR to explore the RNA expression of p16. The expression levels of p16 in these 12 cases were shown in Figure 3 and concomitant to the immunostaining results. The mRNA level of p16 in methylated cases was significantly less than in those without methylation (P Ͻ 0.01). Moreover, in hydatidiform mole cases that subsequently developed gestational trophoblastic neoplasia, the expression of p16 was significantly lower than in hydatidiform moles with spontaneous remission (P ϭ 0.026).
Discussion
Accumulating evidence suggests that changes in gene expression through epigenetic mechanism play important roles for tumor progression. Hydatidiform mole is associated with an increased risk of subsequent development of gestational trophoblastic neoplasia and choriocarcinoma but the mechanism by which such aggressive progression is mediated remains unknown. In this study, a relatively large collection of GTD samples and normal placentas was analyzed for methylation status of six genes which have been found to be frequently meth- ylated in other human cancers. 21, 23 At least one gene was hypermethylated in two-thirds of the hydatidiform mole samples and up to 100% of choriocarcinoma samples. In contrast, no aberrant methylation was detected in 10 normal first trimester placentas at all of the tested genes. This indicated that aberrant CpG island methylation is a frequent and probably disease-restricted event in GTD, including both hydatidiform mole and choriocarcinoma, though more common in choriocarcinoma.
In particular, our data suggested that inactivation of the p16 gene through methylation was more likely to be associated with the malignant transformation of trophoblast. As observed in this study, hypermethylation of p16 occurred more frequently among patients with gestational trophoblastic neoplasia or choriocarcinoma than those with regressed disease.
We also demonstrated that p16 promoter hypermethylation by itself was relatively specific in predicting gestational trophoblastic neoplasia development while combined analysis of p16 and E-cadherin methylation status was more sensitive in such prediction. While methylation status of E-cadherin alone showed no statistically significant correlation with clinical outcome, it improves the sensitivity of predicting gestational trophoblastic neoplasia when analyzed together with p16 methylation status. The methylation of E-cadherin may thus still play a role in the progress of hydatidiform mole. Further studies on may be able to elucidate the mechanisms. On the other hand, combined analysis on the E-cadherin, p16, and HIC-1 methylation status showed no significant correlation to the development of gestational trophoblastic neoplasia. HIC-1 methylation status may not play a role in such disease progress.
p16 encodes a protein belonging to the cyclin-dependent-kinase-inhibit family, inhibits Cdk4/6 and cyclin D association, thus prevents the cell entering the S phase. This phenomenon may be analogous to homozygous deletion, leading to reduced p16 expression and a selective growth advantage for tumor cells. Methylation silencing of p16 was found to be frequent in some types of tumors, including colon, prostate, esophageal, and pancreatic carcinomas. [25] [26] [27] [28] In normal placenta, p16 remains unmethylated, as confirmed in the present report. 29 In GTD, our findings corroborated previous immunohistochemical study in which reduction of p16 expression was observed in malignant trophoblastic tumors. 30 However, this is the first report evaluating the methylation status of p16 and its clinical significance. In this study, we documented a statistically significant correlation between methylation status and expression level of p16 in GTD.
Little is known about the molecular events involved in the pathogenesis of choriocarcinoma. Genes involved in the control of metastatic potential in human cancers, such as nm23, Kiss-1, and E-cadherin have been reported to be down-regulated in choriocarcinoma. 5, 31, 32, 13 Recently, reduced expression of TFPI-2 due to promoter hypermethylation was observed in choriocarcinoma cells. 15 Hypermethylation of TIMP3, which was detected in choriocarcinoma but not in hydatidiform mole in our current study, might be a late event involved in the development and progression of choriocarcinoma. Interestingly, both TFPI-2 and TIMP3 effectively decreased the activation of metalloproteinases, thus inhibiting degradation of the extracellular matrix and reducing the invasive potential of tumor cells. 15, 33 In addition, TIMP3 also has some unique properties in human cancer development, such as growth suppression, 34 inhibition of angiogenesis, 35, 36 and induction of apoptosis. 37, 38 Transcriptional inactivation of TIMP3 by hypermethylation has been found to associated with a more malignant and invasive phenotype in some human cancer cells. 21, 39, 40 Therefore, down-regulation of TIMP3 in choriocarcinoma might be involved in inactivation of several tumor suppressive mechanisms. The accurate roles of TIMP3 in malignant trophoblast remained to be uncovered by further study.
The HIC-1 gene, located on chromosome 17p13.3, is unusual in that the entire gene is contained in a CpG-rich region. Previous studies showed that HIC-1 was commonly hypermethylated and transcriptionally inactivated in leukemia, medulloblastoma, and cancers of breast, prostate, and uterine cervix. 23, [41] [42] [43] [44] In the present study, HIC-1 was the most frequently methylated gene among the panel of genes studied in both hydatidiform moles as well as in choriocarcinoma. This indicated that methylation of HIC-1 might be an early event involved in the pathogenesis of GTD.
Regarding DAPK and GSTP1, we could not detect hypermethylation in either gene in the GTD samples examined. Although these genes were frequently methylated in other tumor types, they were apparently not the targets for methylation in GTD. Similar organ-specific methylation patterns have been reported. 21, 45, 46 Recent improvements in the quality of sonography have resulted in the earlier detection of abnormal pregnancy and earlier evacuation, thus increasing the chances of encountering difficulties in histological distinction between hydatidiform mole and a non-molar abortion exhibiting hydropic change and trophoblast hyperplasia. 4 Given the relative high rate of methylation of HIC-1 and to a lesser extent, p16 and E-cadherin in hydatidiform mole, detection of aberrant methylation of these genes by MSP might be an adjunct tool in differentiating molar and non-molar pregnancy.
The careful follow-up of patients with hydatidiform mole has undoubtedly contributed to the dramatic reduction in mortality from choriocarcinoma. However, such follow-up involves frequent serial clinic visits and ␤-hCG assay, creating burden on both the patients and the community resources. In reality, less than 30% of hydatidiform mole patients need such an intensive care. In addition, much debate exists on the timing regarding initiation of chemotherapy for women at risk for gestational trophoblastic neoplasia. If the patients who will develop gestational trophoblastic neoplasia could be identified at the time of the original diagnosis, there would be a significant benefit in reduction of unnecessary follow-up. The outcome of hydatidiform mole can be evaluated using MSP and immunohistochemical studies on candidate genes immediately after evacuation and the selection of high-risk patients and initiation of prophylactic chemotherapy can thus be guided. Our data suggested that p16 may be a candidate deserving further study.
In conclusion, using candidate genes approach, we found that hypermethylation of tumor suppressor genes frequently occurred in choriocarcinoma and hydatidiform mole. This report provides preliminary evidence that hypermethylation of p16 in relation to its decreased expression might serve as a potential marker predicting subsequent development of gestational trophoblastic neoplasia. However, more conclusive interpretation of our observation needs to be confirmed in further studies involving larger sample size and preferably quantitative methylation study. 
